‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues

It’s been two weeks since Lisa Stockman Mauriello passed away and a lingering question, in my mind, is whether she died in vain.

I’d like to think not.

During her final months, the 52-year-old former public relations executive battled Biogen, one of the world’s largest biotech companies, for access to an experimental treatment for ALS, a fatal neurological disease that gradually causes muscle weakness and paralysis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In